IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award
September 14 2020 - 08:10AM
Business Wire
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical
Outcome Assessment (eCOA) solution, an advanced-study build and
execution platform that optimizes real-time, direct-from-patient
data collection, has been selected as the winner of the Fierce
Innovation Awards – Life Sciences Edition 2020 in the Digital
Health Solutions category. The Fierce Innovation Awards is a
peer-reviewed awards program produced by Questex, the publisher of
Fierce Biotech and Fierce Pharma.
“We are honored to receive this prestigious award, which
showcases outstanding innovation that is driving improvements and
transforming the industry,” said Eric Hodgins, senior vice
president, Real World Technology Solutions at IQVIA. “By building
in the scientific expertise and intelligence needed within the eCOA
technology and incorporating a truly agile development process, we
are dramatically reducing the time to develop these tools while
improving data quality and enhancing the patient experience.”
IQVIA eCOA is built on a highly secure, scalable SaaS platform
that enables faster, flexible startup in clinical research and real
world studies. IQVIA’s eCOA platform cuts up to three months from
the industry standard eCOA development timeline while
simultaneously improving the design through artificial
intelligence-enabled design tools. This allows sponsors to launch
trials faster and ensures the assessments will capture the right
real-time insights to inform trial progress and demonstrate
results.
IQVIA eCOA has a variety of capabilities that enhance the user
experience and lead to time reductions, including a global library
of pre-built assessments, which provides on-demand access to
validated tools that can instantly be deployed. Currently, there
are more than 850 assessments pre-configured in the library across
a multitude of therapeutic areas.
The Fierce Innovation Awards go to companies that demonstrate
innovative technologies and services with the potential to make the
greatest impact for the life sciences industry. The awards
program’s applications are reviewed by an exclusive panel of
executives from major biotech and pharma companies. All honorees
are evaluated based on effectiveness, technical innovation,
competitive advantage, financial impact and true innovation.
Winners were announced in the 2020 Innovation Report published
by Fierce Healthcare in September 2020.
For more information on IQVIA eCOA, please visit
https://www.iqvia.com/solutions/technologies/patient-engagement/ecoa.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies Human Data Science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With approximately
67,000 employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005249/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Feb 2024 to Mar 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2023 to Mar 2024